Researchers Advance Role of Circulating Tumor DNA to Detect Early Melanoma Growth, Uncover Treatment Options

Posted by  | Research, treatment

Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may(...)

A perspective on an immunotherapy clinical trial

Posted by  | Patient Stories

This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel Cancer Center. For more information on Kristina's story, watch her interview with Denise Grady on the New York Times' Facebook page or follow her on Twitter at @kristinabaum. For the post,(...)

One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years

Posted by  | Research

At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma patients who were treated with the immunotherapy drug nivolumab. The drug is currently approved by the U.S. Food and Drug Administration for advanced lung and kidney cancers and advanced melanomas.(...)

Melanoma drug FDA approved

Posted by  | treatment

This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval(...)

Cancer News Review

Posted by  | Research

Cancer headlines this past month included two studies on colonoscopy, a screening tool for colon cancer.  The first study looks at the long-term benefits of colonoscopy and found that 50 percent of colon cancer cases were avoided by a single colonscopy.  In the Cancer News Review podcast, William Nelson, M.D., Ph.D., director of the Johns Hopkins Kimmel Cancer(...)

More Good News on Melanoma Drug

Posted by  | Issues & Perspectives, Research, treatment

Researchers from the Vanderbilt-Ingram Cancer Center and other institutions reported more data today on studies of a new melanoma drug that target products of a cancer-causing mutation in the BRAF gene. The study, published in the New England Journal of Medicine, tracked patients with metastatic melanoma who have been followed for more than a year(...)

Top Trends in Cancer Research 2011

Posted by  | Prevention/Screening, Research

It's been a game-changing year in cancer research.  Doctors and scientists don't typically like to use those words, but here's why I think this is a turning point.  Scientists are churning out the genetic code of cancer cells as quickly as the cost of sequencing technology plummets.   Teams of researchers are looking for ways to add the new armory of cancer cell-targeted(...)